Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Geron Corp. (GERN) Surging Amid Positive Reviews on Clinical Trials

Geron Corp. (NASDAQ:GERN) took a leap by 18.60% to $2.55 on April 10, amid announcing the completion of the second wave of reviews related to clinical trials conducted with Johnson and Johnson subsidiary Janssen Research and Development.

The products include IMerge, or the telomerase inhibitor imetelstat in lower risk myelodysplastic syndromes (MDS); and IMbark or relapsed or refractory myelofibrosis (MF). Geron Corp. (NASDAQ:GERN) said in a press release that the results of imetelstat in treated patients back enduring development in lower risk myelodysplastic syndromes while the IMbark results provide possibilities of survival benefit allied with imetelstat treatment in relapsed or refractory myelofibrosis. Myelodysplastic syndrome is a known cancer.

Geron continues to pursue the trials to review the success rate at a longer period and safety figures while Johnson and Johnson has not given its stance on whether or not it will continue the development.

What Does The Smart Money Sentiment Say?

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).

According to our data, none of the 742 elite funds we track owned any shares of Geron Corp. (NYSE:GERN) at the end of Q4. However, some hedge funds such as Paul Tudor Jones of Tudor Investment Corp. and Ken Griffin of Citadel Investment Group, abandoned their Geron shares by 73% and 61%, respectively.

It should be noted that Jones is known as one of the most successful traders in the past century. His net worth is around $3.3 billion and focuses mainly on short-term trading.

The Bottom Line

Geron Corp. (NASDAQ:GERN) is surging in the trading charts following updates to the reviews related to clinical tests with Johnson & Johnson subsidiary. For more reading, here are 10 countries with the toughest drug laws in the world.

Follow Geron Corp (NASDAQ:GERN)
Trade (NASDAQ:GERN) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
This is a FREE report from Insider Monkey. Credit Card is NOT required.